# An Open Label Phase I Study to Eval the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing ...

> **NCT00924092** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 25 (actual)

## Conditions studied

- Prostate Cancer
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Head and Neck Cancer

## Interventions

- **BIOLOGICAL:** GI-6207 [Recombinant Saccharomyces Cerevisia
- **DRUG:** (Yeast CEA Vaccine)(GI-6207[Recombinant Sarrcharomyces Cerevusua-CEA (610D)])

## Key facts

- **NCT ID:** NCT00924092
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03-13
- **Primary completion:** —
- **Final completion:** 2012-08-02
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2019-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00924092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00924092, "An Open Label Phase I Study to Eval the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing ...". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00924092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*